FIELD: immunology.
SUBSTANCE: disclosed is an antibody which binds to ICOS, or a fragment thereof, a pharmaceutical composition, nucleic acid, an expression vector, a host cell, a host cell for expression. Also disclosed is a method of producing an anti-ICOS antibody, a method of treating cancer, a method for increasing the number of T-effector cells, a method for activating T-effector cells, method for reducing the number of T-regulatory cells. What is also presented is using the antibody or its fragment.
EFFECT: present invention can find further application in therapy of various oncological diseases.
65 cl, 45 dwg, 7 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
